Update to living WHO guideline on drugs for covid-19, BMJ (published/updated 6th July 2021)

The WHO have updated their guidance, now recommending IL-6 receptor blockers (tocilizumab and sarilumab) for severe and critical covid-19, on the basis of the RECOVERY and REMAP-CAP trials. They acknowledge potential access issues around IL-6 receptor blockers.

Source: Current Awareness Service for Health (CASH) - July 8, 2021 Category: Consumer Health News Source Type: news